GlassScriptPhysician profile
Lesley Meng Roth
NPI 1144287137
$1,662.37
in general payments reported to CMS, 2019-2025
17 companies · $68.49 in 2025
The $68.49 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2022: $605 · 2023: $299 · 2024: $575 · 2025: $68.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450 · Long Term Medical Supply Or Device Loan: $399 · Education: $94.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.72 |
| Long Term Medical Supply Or Device Loan | $398.80 |
| Education | $94.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $398.80 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $241.86 | 2022-2025 | Enhertu, Imfinzi |
| Astellas Pharma US INC | $224.61 | 2019-2024 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $178.29 | 2022-2024 | Opdivo, Augtyro, Krazati |
| Adc Therapeutics America, INC. | $125.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $121.87 | 2022 | |
| Merck Sharp & Dohme LLC | $107.52 | 2022 | |
| Janssen Biotech, INC. | $47.90 | 2022 | |
| Pfizer INC. | $35.90 | 2019-2024 | |
| Tactile Systems Technology INC | $30.16 | 2024 | Entre Plus, Flexitouch Plus |
| Csl Behring | $28.77 | 2022 | |
| Tempus Ai, INC | $24.20 | 2024 | |
| Genzyme Corporation | $24.12 | 2022 | |
| Coherus Oncology, INC. | $20.78 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.11 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $17.41 | 2024 | |
| Octapharma USA, INC. | $17.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.